Our research focuses on advanced glycation end products (AGEs) and methylglyoxal (MGO), compounds produced both endogenously and through dietary intake, and their impact on metabolic and vascular health. These processes are deeply intertwined: metabolic dysfunction can trigger inflammation, which in turn compromises vascular integrity, creating a vicious cycle that contributes to chronic diseases such as diabetes, cardiovascular disease, and age-related conditions. Using state-of-the-art mass spectrometry (MS), we measure a broad panel of dicarbonyls, AGEs, and oxidative stress markers in plasma, urine, and tissues. This technique forms the cornerstone of his research. We also employ biochemical assays, molecular biology techniques, and advanced imaging tools, enabling exploration of the sources, dynamics, and effects of these compounds.

Our investigations span laboratory models and human populations, including large cohort studies such as The Maastricht Study. This combined approach bridges molecular analyses with physiological and clinical outcomes, helping to identify early markers of disease risk and progression. By integrating advanced analytical techniques with vascular imaging and wire myography, we aim to develop targeted interventions and preventive measures that promote healthier metabolic and vascular systems while addressing the broader societal challenges of aging and chronic disease.

Lead scientist

Philippe Vangrieken